---
title: Supratherapeutic INR
authors:
    - Michelle Lin, MD
created: 2012/08/10
updates:
categories:
    - Hematology and Oncology
---

# Overanticoagulation and Supratherapeutic INR from Warfarin

**ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)**

|         INR | Therapeutic Intervention                                                                                                                                                                                                                      |
| ----------: | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
|      &le;10 | **_If no bleeding:_** Hold <span class="drug">coumadin</span>. Restart when INR is therapeutic                                                                                                                                                |
|      &gt;10 | **_If no bleeding:_** Hold <span class="drug">coumadin</span>. Give oral <span class="drug">vitamin K</span> (2.5 mg)                                                                                                                         |
| Major bleed | Hold <span class="drug">coumadin</span>. Give <span class="drug">vitamin K</span> (5-10 mg slow IVP), 4-factor <span class="drug">PCC</span> (<span class="drug">FFP</span> not of added benefit with 4-factor <span class="drug">PCC</span>) |

**Higher bleeding risk associated with coumadin**

- NSAIDS: non-selective and COX-2 selective
- Antiplatelet agents: <span class="drug">aspirin</span>, <span class="drug">clopidogrel</span>
- <span class="drug">Clotrimoxazole</span>
- Antibiotics (especially <span class="drug">fluoroquinolones</span>)

**Pearl**

- Risk of intracranial hemorrhage doubles for every 1-point increase in INR

## Causes for supratherapeutic INR >6

[Hylek et al. JAMA 1998 study](https://www.ncbi.nlm.nih.gov/pubmed/9496982)

- Retrospective case-control study of patients with INR >6
- Enrolled 93 cases, 196 controls

<table>
<colgroup>
<col width="50%" />
<col width="50%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk Factor / Explanation</strong></th>
<th><strong>Odds Ratio</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Advanced malignancy</td>
<td>16.4</td>
</tr>
<tr class="even">
<td><strong></strong>
<p><span class="drug">Acetaminophen intake</span><br/> • 4.5-9.1 g/wk<br />
• &gt; 9.1 g/wk</p></td>
<td>6.8<br />
10<br /></td>
</tr>
<tr class="odd">
<td>New medication</td>
<td>8.5</td>
</tr>
<tr class="even">
<td>Excess <span class="drug">coumadin</span> intake</td>
<td>8.1</td>
</tr>
<tr class="odd">
<td>Decreased oral intake</td>
<td>3.6</td>
</tr>
<tr class="even">
<td>Acute diarrheal illness</td>
<td>3.5</td>
</tr>
<tr class="odd">
<td>Vitamin K intake</td>
<td>0.7</td>
</tr>
<tr class="even">
<td>Alcohol use<br />
(1 drink QOD-2 drinks daily)</td>
<td>0.2</td>
</tr>
</tbody>
</table>

## References

- Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9496982)]
- Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22315259)]
